2 results
Approved WMOCompleted
Primary: to assess the efficacy of ambrisentan 5mg after treatment period of 16 weeks, in subjects with inoperable CTEPH. Secondary: safety and tolerability.
Approved WMOCompleted
Using the model of lipid-induced insulin resistance we will study the hypothesis that pre-treatment with salsalate (salicylsalicylic acid) blunts the development of lipid-induced insulin resistant in an I*B/NF*B dependent manner in healthy human…